 |
 |
|
|
|  PubMed
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 January 1995 | Volume 122 Issue 1 | Pages 33-39
Objective: To compare the efficacy of mannose-terminated glucocerebrosidase prepared from natural (alglucerase; Ceredase, Genzyme Corp., Cambridge, Massachusetts) and recombinant (imiglucerase; Cere-zyme, Genzyme Corp.) sources in treating type 1 Gaucher disease.
Design: Double-blind, randomized, parallel trial.
Setting: University medical center and clinical research hospital.
Patients: 15 patients (4 children and 11 adults) randomly assigned to receive Ceredase and 15 patients (3 children and 12 adults) assigned to receive Cerezyme.
Intervention: Ceredase and Cerezyme were infused every 2 weeks for 9 months at a dose of 60 U/kg body weight.
Outcome Measures: Hemoglobin levels, platelet counts, and serum acid phosphatase and angiotensin-converting enzyme activities were monitored every 2 weeks during the trial. Hepatic and splenic volumes were assessed at the time of randomization and after 6 and 9 months of enzyme infusion. Formation of IgG antibodies to Ceredase or Cerezyme was monitored every 3 months by radioimmunoprecipitation assay.
Results: No significant differences were found in the rate or extent of improvement in hemoglobin levels, platelet counts, serum acid phosphatase or angiotensin-converting enzyme activities, or hepatic or splenic volumes between either treatment group. The incidence of IgG antibody formation was greater in the Ceredase group (40%) than in the Cerezyme group (20%). No major immunologic adverse events occurred in either group.
Conclusions: Our study shows the therapeutic similarity of Ceredase and Cerezyme. Cerezyme has the advantage of being theoretically unlimited in supply and free of potential pathogenic contaminants.
Author and Article Information
From Children's Hospital Medical Center, Cincinnati, Ohio; Mt. Sinai School of Medicine, New York, New York; and the National Institute of Neurological Disorders and Strokes, Bethesda, Maryland.
ARTICLE
Enzyme Therapy in Type 1 Gaucher Disease: Comparative Efficacy of Mannose-terminated Glucocerebrosidase from Natural and Recombinant Sources
Requests for Reprints: Gregory A. Grabowski, MD, Children's Hospital Medical Center, Division of Human Genetics, Pavilion 3-52, 3333 Burnet Avenue, Cincinnati, OH 45229-3039.
Grant Support: A grant to Dr. Grabowski supported only and in toto the patient-related study costs. Other grant support was provided by the General Clinical Research Center at Mt. Sinai Medical Center (grant 2 M01 00071) and the Markey Center for Pediatric Molecular Genetics at the Children's Hospital Medical Center, Cincinnati, Ohio.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Facebook 
Reddit 
Technorati 
Twitter What's this?
This article has been cited by other articles:
|
|
 |
|
  H. Andersson, P. Kaplan, K. Kacena, and J. Yee Eight-Year Clinical Outcomes of Long-Term Enzyme Replacement Therapy for 884 Children With Gaucher Disease Type 1 Pediatrics, December 1, 2008; 122(6): 1182 - 1190. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-R. Alattia, J. E. Shaw, C. M. Yip, and G. G. Prive Molecular imaging of membrane interfaces reveals mode of beta-glucosidase activation by saposin C PNAS, October 30, 2007; 104(44): 17394 - 17399. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. B. Enquist, C. L. Bianco, A. Ooka, E. Nilsson, J.-E. Mansson, M. Ehinger, J. Richter, R. O. Brady, D. Kirik, and S. Karlsson Murine models of acute neuronopathic Gaucher disease PNAS, October 30, 2007; 104(44): 17483 - 17488. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Van Patten, H. Hughes, M. R. Huff, P. A. Piepenhagen, J. Waire, H. Qiu, C. Ganesa, D. Reczek, P. V. Ward, J. P. Kutzko, et al. Effect of mannose chain length on targeting of glucocerebrosidase for enzyme replacement therapy of Gaucher disease Glycobiology, May 1, 2007; 17(5): 467 - 478. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Schmitz, L. W. Poll, and S. v. Dahl Therapy of adult Gaucher disease Haematologica, February 1, 2007; 92(2): 148 - 152. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kudo, M. Bao, A. D'Souza, F. Ying, H. Pan, B. A. Roe, and W. M. Canfield The {alpha}- and {beta}-subunits of the Human UDP-N-acetylglucosamine:Lysosomal Enzyme Phosphotransferase Are Encoded by a Single cDNA J. Biol. Chem., October 28, 2005; 280(43): 36141 - 36149. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Zhu, X. Li, J. Kyazike, Q. Zhou, B. L. Thurberg, N. Raben, R. J. Mattaliano, and S. H. Cheng Conjugation of Mannose 6-Phosphate-containing Oligosaccharides to Acid {alpha}-Glucosidase Improves the Clearance of Glycogen in Pompe Mice J. Biol. Chem., November 26, 2004; 279(48): 50336 - 50341. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. S. Prince, L. M. McCormick, D. J. Wendt, P. A. Fitzpatrick, K. L. Schwartz, A. I. Aguilera, V. Koppaka, T. M. Christianson, M. C. Vellard, N. Pavloff, et al. Lipoprotein Receptor Binding, Cellular Uptake, and Lysosomal Delivery of Fusions between the Receptor-associated Protein (RAP) and {alpha}-L-Iduronidase or Acid {alpha}-Glucosidase J. Biol. Chem., August 13, 2004; 279(33): 35037 - 35046. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L W Poll, M Maas, M R Terk, M Roca-Espiau, B Bembi, G Ciana, and N J Weinreb Response of Gaucher bone disease to enzyme replacement therapy Br. J. Radiol., May 24, 2002; 75(90001): A25 - 36. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Charrow, H. C. Andersson, P. Kaplan, E. H. Kolodny, P. Mistry, G. Pastores, B. E. Rosenbloom, C. R. Scott, R. S. Wappner, N. J. Weinreb, et al. The Gaucher Registry: Demographics and Disease Characteristics of 1698 Patients With Gaucher Disease Arch Intern Med, October 9, 2000; 160(18): 2835 - 2843. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Jeyakumar, T. D. Butters, M. Cortina-Borja, V. Hunnam, R. L. Proia, V. H. Perry, R. A. Dwek, and F. M. Platt Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin PNAS, May 25, 1999; 96(11): 6388 - 6393. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Friedman, K. Vaddi, C. Preston, E. Mahon, J. R. Cataldo, and J. M. McPherson A Comparison of the Pharmacological Properties of Carbohydrate Remodeled Recombinant and Placental-Derived beta -Glucocerebrosidase: Implications for Clinical Efficacy in Treatment of Gaucher Disease Blood, May 1, 1999; 93(9): 2807 - 2816. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. W. Kennedy and J. L. Abkowitz Mature monocytic cells enter tissues and engraft PNAS, December 8, 1998; 95(25): 14944 - 14949. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Charrow, J. A. Esplin, T. J. Gribble, P. Kaplan, E. H. Kolodny, G. M. Pastores, C. R. Scott, R. S. Wappner, N. J. Weinreb, and J. S. Wisch Gaucher Disease: Recommendations on Diagnosis, Evaluation, and Monitoring Arch Intern Med, September 14, 1998; 158(16): 1754 - 1760. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Ponce, J. Moskovitz, and G. Grabowski Enzyme Therapy in Gaucher Disease Type 1: Effect of Neutralizing Antibodies to Acid beta -Glucosidase Blood, July 1, 1997; 90(1): 43 - 48. [Abstract] [Full Text] [PDF]
|
|
